Literature DB >> 6981814

Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis.

A Van Pel, T Boon.   

Abstract

The nonimmunogenic thymic leukemia TH, obtained in mouse strain CBA/Ht, was adapted to culture. By in vitro treatment of a clonal TH cell line with the mutagen N-methyl-N'-nitro-N-nitrosoguanidine, stable variant cell clones (tum-) were obtained that elicited a rejection response in syngeneic mice. Mice that had rejected a tum- variant were partially protected against a challenge with the original tumor. When spleen cells of these animals were restimulated in vitro, cytolytic T cells were obtained that were directed against an antigen present on the original tumor. The existence of these cytolytic effectors was confirmed by clonal analysis of the cytolytic response. No immune protection against TH was observed in mice that had been immunized with irradiated cells of the original TH tumor. These results confirm that tum- variants can elicit a syngeneic rejection response against tumors that are apparently devoid of transplantation immunogenicity. The experimental conditions and the results make it likely but not certain that the tumor-associated antigen detected on leukemia TH was present on the primary tumor.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6981814      PMCID: PMC346748          DOI: 10.1073/pnas.79.15.4718

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Immunity to methylcholanthrene-induced sarcomas.

Authors:  R T PREHN; J M MAIN
Journal:  J Natl Cancer Inst       Date:  1957-06       Impact factor: 13.506

2.  Limiting dilution analysis of alloantigen-reactive T lymphocytes. I. Comparison of precursor frequencies for proliferative and cytolytic responses.

Authors:  J E Ryser; H R MacDonald
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

3.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.

Authors:  C Uyttenhove; J Van Snick; T Boon
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

Review 4.  Quantitation and cloning of cytolytic T lymphocytes and their precursors.

Authors:  H R MacDonald; J C Cerottini; J E Ryser; J L Maryanski; C Taswell; M B Widmer; K T Brunner
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

Review 5.  Interleukin-2 dependent culture of cytolytic T cell lines.

Authors:  S Gillis; J Watson
Journal:  Immunol Rev       Date:  1981       Impact factor: 12.988

6.  Immunogenic cell variants of a mouse teratocarcinoma confer a protection against the original non-immunogenic transplantable tumor.

Authors:  M Georlette; T Boon
Journal:  Eur J Cancer Clin Oncol       Date:  1981-10

7.  Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice.

Authors:  A Van Pel; M Georlette; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

Review 8.  Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

Authors:  L J Old
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

9.  Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells.

Authors:  K T Brunner; H R MacDonald; J C Cerottini
Journal:  J Immunol       Date:  1980-04       Impact factor: 5.422

10.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.

Authors:  T Boon; J Van Snick; A Van Pel; C Uyttenhove; M Marchand
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

View more
  30 in total

1.  Cancer immunotherapy: in vivo imaging of adoptively transferred T cells in an immunocompetent host.

Authors:  Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-29       Impact factor: 11.205

2.  Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism.

Authors:  Christopher G Twitty; Shawn M Jensen; Hong-Ming Hu; Bernard A Fox
Journal:  Clin Cancer Res       Date:  2011-08-02       Impact factor: 12.531

Review 3.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

Review 4.  New therapeutic approaches based on gene transfer techniques.

Authors:  H Chong; R G Vile
Journal:  Springer Semin Immunopathol       Date:  1996

Review 5.  Biological treatment for liver tumor and new potential biomarkers.

Authors:  Maurizio Chiriva-Internati; Fabio Grizzi; Mitchell S Wachtel; Marjorie Jenkins; Raffaele Ferrari; Everardo Cobos; Eldo E Frezza
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

6.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

Review 7.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

Review 8.  Immunotherapy of cancer: from vision to standard clinical practice.

Authors:  Christoph H Huber; Thomas Wölfel
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

Review 9.  ProtEx technology for the generation of novel therapeutic cancer vaccines.

Authors:  Rich-Henry Schabowsky; Rajesh K Sharma; Shravan Madireddi; Abhishek Srivastava; Esma S Yolcu; Haval Shirwan
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

10.  Enhanced tumor susceptibility of immunocompetent mice infected with lymphocytic choriomeningitis virus.

Authors:  M Kohler; B Rüttner; S Cooper; H Hengartner; R M Zinkernagel
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.